Next |
home / stock / athe / athe message board
Subject | By | Source | When |
---|---|---|---|
she will soon enough my friend! athe volume | NYCJR | investorshub | 07/18/2022 9:56:04 PM |
soo oversold its not even funny, also float | NYCJR | investorshub | 07/18/2022 4:14:36 PM |
more news should be coming in the next | NYCJR | investorshub | 07/18/2022 4:14:03 PM |
remember folks, this ran hard around this time | NYCJR | investorshub | 07/18/2022 4:13:25 PM |
building myself a nice little position here folks! | NYCJR | investorshub | 07/16/2022 1:02:13 AM |
From the sticky... | XenaLives | investorshub | 01/07/2022 9:36:31 PM |
Alterity Therapeutics Granted New US Patent for Compounds | shamalamadingdong | investorshub | 01/06/2022 10:53:54 AM |
Roar! | Byurwherevergirl | investorshub | 07/16/2021 6:58:20 AM |
28 thousand revenues VS. over 70 million Market | make it happen | investorshub | 07/15/2021 7:20:43 PM |
$ATHE released news hasnt hit wires gap watch | stock1ace1 | investorshub | 07/15/2021 2:46:10 AM |
Chart -- $ATHE | conix | investorshub | 07/08/2021 8:17:42 PM |
Testing the waters here. Close looked interesting. Maybe | FrankyFresh | investorshub | 07/02/2021 1:42:52 AM |
znewcar1: ATHE 64% v239M c2.14 f34,7M H2.75 S2 | znewcar1 | investorshangout | 07/01/2021 8:11:38 PM |
Added 2.08! | Surfacetite | investorshub | 07/01/2021 4:43:38 PM |
Wow float is locked | INFINITI | investorshub | 07/01/2021 4:41:24 PM |
Look again | INFINITI | investorshub | 07/01/2021 2:27:44 PM |
Off a patent? Nah | Hattori Hanzo | investorshub | 07/01/2021 1:40:26 PM |
Alterity Therapeutics granted a new US patent targeting | INFINITI | investorshub | 07/01/2021 12:23:53 PM |
Looking like we got a RUNNER | INFINITI | investorshub | 07/01/2021 12:22:54 PM |
I think many of US are lurking this | Yki | investorshub | 05/24/2021 3:03:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
Alterity Therapeutics Limited Website:
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...